[6-K] OKYO Pharma Ltd Current Report (Foreign Issuer)
OKYO Pharma reported that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 210,000 of the company’s ordinary shares on NASDAQ. Following this purchase, his total holding is 10,382,677 shares. The news announcement was furnished as Exhibit 99.1 and is not deemed filed under Section 18 of the Exchange Act.
OKYO Pharma ha riferito che Panetta Partners Limited, una società in cui il Presidente Esecutivo Gabriele Cerrone detiene un interesse economico, ha acquisito 210.000 delle azioni ordinarie della società su NASDAQ. A seguito di questo acquisto, la sua partecipazione totale ammonta a 10.382.677 azioni. L'annuncio stampa è stato fornito come Allegato 99.1 e non è considerato depositato ai sensi della Sezione 18 del Securities Exchange Act.
OKYO Pharma informó que Panetta Partners Limited, una entidad en la que el presidente ejecutivo Gabriele Cerrone tiene un interés beneficioso, adquirió 210,000 de las acciones ordinarias de la empresa en NASDAQ. Tras esta compra, su participación total es de 10,382,677 acciones. El anuncio de noticias se presentó como el Exhibit 99.1 y no se considera presentado en virtud de la Sección 18 de la Securities Exchange Act.
OKYO Pharma가 Executive Chairman Gabriele Cerrone이 실질적 이해관계를 가진 Panetta Partners Limited가 회사의 보통주 210,000주를 NASDAQ에서 인수했다고 보고했습니다. 이 매입 이후 그의 총 보유주식은 10,382,677주입니다. 이 보도 발표는 Exhibit 99.1로 제출되었으며 Exchange Act의 섹션 18에 따라 filed로 간주되지 않습니다.
OKYO Pharma a indiqué que Panetta Partners Limited, une entité dans laquelle le président exécutif Gabriele Cerrone détient un intérêt, a acquis 210 000 des actions ordinaires de la société sur NASDAQ. Suite à cet achat, sa participation totale s’élève à 10 382 677 actions. L’annonce de presse a été fournie comme Exhibit 99.1 et n’est pas réputée déposée en vertu de la Section 18 du Securities Exchange Act.
OKYO Pharma berichtete, dass Panetta Partners Limited, eine Gesellschaft, an der der Executive Chairman Gabriele Cerrone eine wirtschaftliche Beteiligung hat, 210.000 der stimmberechtigten Aktien des Unternehmens an der NASDAQ erworben hat. Nach diesem Kauf beträgt seine Gesamtbeteiligung 10.382.677 Aktien. Die Pressemitteilung wurde als Exhibit 99.1 bereitgestellt und gilt nicht als unter Section 18 des Exchange Act eingereicht.
OKYO Pharma ذكرت أن Panetta Partners Limited، وهي جهة تملك فيها رئيس مجلس الإدارة التنفيذي غابرييلي سيروني مصلحة مفيدة، قد اشترت 210,000 من أسهم الشركة العادية في NASDAQ. وبعد هذه الصفقة، أصبحت حصته الإجمالية 10,382,677 سهماً. وقد تم تزويد إعلان الخبر كمعرض 99.1 وهو لا يعتبر مُسجلاً وفقاً للقسم 18 من قانون بورس المستندات.
OKYO Pharma 报告称，Panetta Partners Limited——一家公司，执行主席 Gabriele Cerrone 持有利益——已在纳斯达克购买了 210,000 股公司的普通股。此交易后，他的总持股为 10,382,677 股。该新闻公告以 Exhibit 99.1 的形式提供，不被视为依据交易法第18条备案。
- None.
- None.
Insights
Insider‑affiliated purchase disclosed; administrative and informational.
OKYO Pharma disclosed that Panetta Partners Limited, linked to Executive Chairman Gabriele Cerrone, acquired 210,000 shares on NASDAQ, bringing his total to 10,382,677 shares. This is an informational update via a furnished exhibit.
The event indicates increased holdings by an insider‑affiliated entity; however, the disclosure does not provide pricing, rationale, or implications beyond the updated stake. It does not alter capital structure through issuance.
The announcement is furnished as Exhibit 99.1 and “shall not be deemed filed,” which limits potential liabilities under Section 18. Subsequent company filings may provide additional context.
OKYO Pharma ha riferito che Panetta Partners Limited, una società in cui il Presidente Esecutivo Gabriele Cerrone detiene un interesse economico, ha acquisito 210.000 delle azioni ordinarie della società su NASDAQ. A seguito di questo acquisto, la sua partecipazione totale ammonta a 10.382.677 azioni. L'annuncio stampa è stato fornito come Allegato 99.1 e non è considerato depositato ai sensi della Sezione 18 del Securities Exchange Act.
OKYO Pharma informó que Panetta Partners Limited, una entidad en la que el presidente ejecutivo Gabriele Cerrone tiene un interés beneficioso, adquirió 210,000 de las acciones ordinarias de la empresa en NASDAQ. Tras esta compra, su participación total es de 10,382,677 acciones. El anuncio de noticias se presentó como el Exhibit 99.1 y no se considera presentado en virtud de la Sección 18 de la Securities Exchange Act.
OKYO Pharma가 Executive Chairman Gabriele Cerrone이 실질적 이해관계를 가진 Panetta Partners Limited가 회사의 보통주 210,000주를 NASDAQ에서 인수했다고 보고했습니다. 이 매입 이후 그의 총 보유주식은 10,382,677주입니다. 이 보도 발표는 Exhibit 99.1로 제출되었으며 Exchange Act의 섹션 18에 따라 filed로 간주되지 않습니다.
OKYO Pharma a indiqué que Panetta Partners Limited, une entité dans laquelle le président exécutif Gabriele Cerrone détient un intérêt, a acquis 210 000 des actions ordinaires de la société sur NASDAQ. Suite à cet achat, sa participation totale s’élève à 10 382 677 actions. L’annonce de presse a été fournie comme Exhibit 99.1 et n’est pas réputée déposée en vertu de la Section 18 du Securities Exchange Act.
OKYO Pharma berichtete, dass Panetta Partners Limited, eine Gesellschaft, an der der Executive Chairman Gabriele Cerrone eine wirtschaftliche Beteiligung hat, 210.000 der stimmberechtigten Aktien des Unternehmens an der NASDAQ erworben hat. Nach diesem Kauf beträgt seine Gesamtbeteiligung 10.382.677 Aktien. Die Pressemitteilung wurde als Exhibit 99.1 bereitgestellt und gilt nicht als unter Section 18 des Exchange Act eingereicht.
FAQ
What did OKYO (OKYO) disclose in its Form 6-K?
How many OKYO shares were acquired and what is the new total holding?
Who is Panetta Partners Limited in relation to OKYO?
Where was the acquisition of OKYO shares executed?
Is the news announcement part of the official record or just furnished?
What is the exhibit number and date for the announcement?
